Structural difference in the complement activation site of human IgG1 and IgG3

Scandinavian Journal of Immunology

Volumn 70, Issue 6, 2009, Pages 553-564

  Michaelsen, T E ^a,b   Sandlie, I ^b   Bratlie, D B ^a   Sandin, R H ^a   Ihle, O ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ANTIGEN; ASPARTIC ACID; COMPLEMENT COMPONENT C1Q; HAPTEN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G3 ANTIBODY; LEUCINE;

ANIMAL CELL; ARTICLE; BINDING SITE; COMPARATIVE STUDY; COMPLEMENT ACTIVATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GUINEA PIG; HINGE REGION; HUMAN; LYSIS; MUTANT; MUTATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; SERUM; TARGET CELL;

ANIMALS; ANTIBODY AFFINITY; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BINDING SITES, ANTIBODY; COMPLEMENT ACTIVATION; COMPLEMENT C1Q; GUINEA PIGS; HUMANS; IMMUNOGLOBULIN G; MUTATION; NITROHYDROXYIODOPHENYLACETATE; RABBITS;

EID: 70449825100     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2009.02338.x     Document Type: Article

References (41)

1. Burton DR, Boyd J, Brampton AD et al. The Clq receptor site on immunoglobulin G. Nature 1980 288 : 338 344.
2. Colomb M, Porter RR. Characterization of a plasmin-digest fragment of rabbit immunoglobulin gamma that binds antigen and complement. Biochem J 1975 145 : 177 183.
3. Connell GE, Porter RR. A new enzymic fragment (Facb) of rabbit immunoglobulin G. Biochem J 1971 124 : 53P.
4. Painter RH, Foster DB, Gardner B, Hughes-Jones NC. Functional affinity constants of subfragments of immunoglobulin G for Clq. Mol Immunol 1982 19 : 127 131.
5. Tao MH, Canfield SM, Morrison SL. The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain. J Exp Med 1991 173 : 1025 1028.
6. Yasmeen D, Ellerson JR, Dorrington KJ, Painter RH. The structure and function of immunoglobulin domains. IV. The distribution of some effector functions among the Cgamma2 and Cgamma3 homology regions of human immunoglobulin G1. J Immunol 1976 116 : 518 526.
7. Idusogie EE, Presta LG, Gazzano-Santoro H et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 2000 164 : 4178 4184.
8. Thommesen JE, Michaelsen TE, Loset GA, Sandlie I, Brekke OH. Lysine 322 in the human IgG3 C(H)2 domain is crucial for antibody dependent complement activation. Mol Immunol 2000 37 : 995 1004.
9. Bruggemann M, Williams GT, Bindon CI et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 1987 166 : 1351 1361.
10. Michaelsen TE, Garred P, Aase A. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur J Immunol 1991 21 : 11 6.
11. Lucisano Valim YM, Lachmann PJ. The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin Exp Immunol 1991 84 : 1 8.
12. Norderhaug L, Olafsen T, Michaelsen TE, Sandlie I. Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells. J Immunol Methods 1997 204 : 77 87.
13. Berntzen G, Lunde E, Flobakk M, Andersen JT, Lauvrak V, Sandlie I. Prolonged and increased expression of soluble Fc receptors, IgG and a TCR-Ig fusion protein by transiently transfected adherent 293E cells. J Immunol Methods 2005 298 : 93 104.
14. Michaelsen TE, Ihle O, Beckstrom KJ et al. Binding properties and anti-bacterial activities of V-region identical, human IgG and IgM antibodies, against group B Neisseria meningitidis. Biochem Soc Trans 2003 5 : 1032 1035.
15. Michaelsen TE, Ihle O, Beckstrom KJ et al. Construction and functional activities of chimeric mouse-human immunoglobulin G and Immunoglobulin M antibodies against the Neisseria meningitidis PorA P1.7 and P1.16 Epitopes. Infect Immun 2003 71 : 5714 5723.
16. Michaelsen TE, Aase A, Norderhaug L, Sandlie I. Antibody dependent cell-mediated cytotoxicity induced by chimeric mouse-human IgG subclasses and IgG3 antibodies with altered hinge region. Mol Immunol 1992 29 : 319 326.
17. Aase A, Michaelsen TE. The use of a hapten-Fab conjugate to sensitize target cells for antibody-dependent complement-mediated lysis and antibody-dependent cell-mediated cytotoxicity. J Immunol Methods 1991 136 : 185 191.
18. Michaelsen TE, Brekke OH, Aase A, Sandin RH, Bremnes B, Sandlie I. One disulfide bond in front of the second heavy chain constant region is necessary and sufficient for effector functions of human IgG3 without a genetic hinge. Proc Natl Acad Sci USA 1994 91 : 9243 9247.
19. Sandlie I, Aase A, Westby C, Michaelsen TE. C1q binding to chimeric monoclonal IgG3 antibodies consisting of mouse variable regions and human constant regions with shortened hinge containing 15 to 47 amino acids. Eur J Immunol 1989 19 : 1599 1603.
20. Duncan AR, Winter G. The binding site for C1q on IgG. Nature 1988 332 : 738 740.
21. Morgan A, Jones ND, Nesbitt AM, Chaplin L, Bodmer MW, Emtage JS. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding. Immunology 1995 86 : 319 324.
22. Tao MH, Smith RI, Morrison SL. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med 1993 178 : 661 667.
23. Xu Y, Oomen R, Klein MH. Residue at position 331 in the IgG1 and IgG4 CH2 domains contributes to their differential ability to bind and activate complement. J Biol Chem 1994 269 : 3469 3474.
24. Michaelsen TE, Aase A, Westby C, Sandlie I. Enhancement of complement activation and cytolysis of human IgG3 by deletion of hinge exons. Scand J Immunol 1990 32 : 517 528.
25. Imanishi T, Makela O. Inheritance of antibody specificity. I. Anti-(4-hydroxy-3-nitrophenyl)acetyl of the mouse primary response. J Exp Med 1974 140 : 1498 1510.
26. Frangione B, Milstein C, Pink JR. Structural studies of immunoglobulin G. Nature 1969 221 : 145 148.
27. Michaelsen TE, Natvig JB. The hinge region of IgG3, an extended part of the molecule. FEBS Lett 1972 28 : 121 124.
28. Michaelsen TE, Natvig JB, Sletten K. Isolation of a fragment, Fh, corresponding to the hinge region of human IgG3. Scand J Immunol 1974 3 : 491 498.
29. Michaelsen TE, Natvig JB. Unusual molecular properties of human IgG3 proteins due to an extended hinge region. J Biol Chem 1974 249 : 2778 2785.
30. Huck S, Fort P, Crawford DH, Lefranc MP, Lefranc G. Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: comparison with the other human C gamma genes. Nucleic Acids Res 1986 4 : 1779 1789.
31. Michaelsen TE, Frangione B, Franklin EC. Primary structure of the "hinge" region of human IgG3. Probable quadruplication of a 15-amino acid residue basic unit. J Biol Chem 1977 252 : 883 889.
32. Brekke OH, Michaelsen TE, Sandlin R, Sandlie I. Activation of complement by an IgG molecule without a genetic hinge. Nature 1996 383 : 103.
33. Michaelsen TE, Thommesen JE, Ihle O et al. A mutant human IgG molecule with only one C1q binding site can activate complement and induce lysis of target cells. Eur J Immunol 2006 36 : 129 138.
34. Garred P, Michaelsen TE, Aase A. The IgG subclass pattern of complement activation depends on epitope density and antibody and complement concentration. Scand J Immunol 1989 30 : 379 382.
35. Naess LM, Aarvak T, Aase A et al. Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine. Vaccine 1999 8 : 754 764.
36. Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest 1970 49 : 673 680.
37. Saeland E, Vidarsson G, Leusen JH et al. Central role of complement in passive protection by human IgG1 and IgG2 anti-pneumococcal antibodies in mice. J Immunol 2003 170 : 6158 6164.
38. Roux KH, Strelets L, Michaelsen TE. Flexibility of human IgG subclasses. J Immunol 1997 159 : 3372 3382.
39. Idusogie EE, Wong PY, Presta LG et al. Engineered antibodies with increased activity to recruit complement. J Immunol 2001 166 : 2571 2575.
40. Lefranc MP, Helal AN, de LG, Chaabani H, van LE, Lefranc G. Gene conversion in human immunoglobulin gamma locus shown by unusual location of IgG allotypes. FEBS Lett 1986 196 : 96 102.
41. Nielsen LK, Green TH, Sandlie I, Michaelsen TE, Dziegiel MH. In vitro assessment of recombinant, mutant immunoglobulin G anti-D devoid of hemolytic activity for treatment of ongoing hemolytic disease of the fetus and newborn. Transfusion 2008 48 : 12 9.